Labor Day heralds the unofficial end of summer. At NATF, we’ve had our busiest and most productive summer ever. We hired two new staff members, launched improvements in our website, held informational meetings about thrombosis in diverse communities, and put the finishing touches on our 8th Thrombosis Summit, to be held on Saturday morning, September 20, at the Fairmont Copley Plaza Hotel in Boston.
Click here to read the full letter.
NATF has collaborated with the Patient Centered Outcomes Research Institute (PCORI), and the Johns Hopkins Medicine Institutional Review Board, to embark on an important project to build patient education for the prevention of venous thromboembolism (VTE). Scroll down to participate in this project!
My experience with DVT/PE
"Being a Senator, I used to travel a lot, both within and outside the U.S. I was always in good health, my husband being a cardiologist. In 2001, I travelled with my family to San Diego, California, for a legislative convention. One afternoon, I was walking up a flight of stairs in a pair of flat sandals when I suddenly tripped on the edge of a step and immediately felt acute pain in my leg..."
My family experience with DVT/PE
"What is our story? I had a PE 15 years ago and a DVT a year later. The first question I am always asked is what were the symptoms. For the PE, I had no symptoms until I had shortness of breath and a rapid pulse for no apparent reason ... We did think it was genetic, because my father’s mother had died abruptly after surgery. When my mother had a PE at 98, I found it was on both sides of my family."
'American Idol' finalist Michael Johns dead at 35
(CNN) 4 August 2014 -- A one-time "American Idol" finalist has died, the show's official Facebook page announced.
"Michael Johns was an incredible talent and we are deeply saddened by the news of his passing," a joint statement from Fox, FremantleMedia North America and 19 Entertainment said.
Read the full article.
Deep vein thrombosis: a silent danger
NATF member Atul Laddu, MD, PhD, FACC raises DVT awareness with an article published in the September/October issue of Healthy Living Made Simple. Dr. Laddu writes, "A current study from the American Heart Association estimates the total econmic burden of illness associated with DVT and PE to reach between $5-8 billion annually--an average of $20,000 per treated patient per year. The good news? These conditions are entirely preventable."
2014 Thrombosis Summit Video
Dr. Goldhaber discusses NATF's upcoming Thrombosis Weekend, which will take place at the Fairmont Copley Plaza Hotel in Boston, September 19-20.
To register, visit: www.regonline.com/NATFsummit
New CMEducation program
Program Co-Chairs Samuel Z. Goldhaber, MD and Christian T. Ruff, MD, of Harvard Medical School, discuss the foundation role of oral Factor Xa and direct thrombin inhibitors stroke prevention in atrial firbrillation and acute treatment of VTE.
First recommendations on all new oral anticoagulants in pulmonary embolism published
Science Newsline: 1 September 2014 - The first recommendations on the use of all new oral anticoagulants in pulmonary embolism are published today in new ESC Guidelines. The guidelines are launched at ESC Congress by Professor Stavros V. Konstantinides (Germany/Greece) and Professor Adam Torbicki (Poland).
Exercise May Shield Older Women From Afib
MedPage Today: 22 August 2014 - High-intensity exercise was tied to a reduced risk for atrial fibrillation in post-menopausal women and obese women in particular, researchers said.
FDA approves use of Eliquis to treat leg, lung clots
Reuters: 21 August 2014 - Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.
The drugmakers said the U.S. Food and Drug Administration also approved use of the pill to reduce risk of recurrent blood clots in the deep veins of the leg, called deep vein thrombosis, and in the lung, called pulmonary embolism, following initial therapy.